NYU Langone Medical Center researchers have found a biological weakness in the workings of the most commonly mutated gene involved in human cancers, known as mutant K-Ras, which they say can be exploited by drug chemotherapies to thwart tumor growth.
Mutant K-Ras has long been suspected of being the driving force behind more than a third of all cancers, including colon, lung, and a majority of pancreatic cancers. Indeed, Ras cancers, which are unusually aggressive, are thought of as "undruggable" because every previous attempt to stall their growth has failed.